Previsioni

Il prezzo obiettivo medio degli analisti è +53,91€ (+19,64%). La mediana è +55,80€ (+23,83%).

Acquista	5
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Rapport Therapeutics reaches record high at $44.38

Rapport Therapeutics shares rose to a new all-time high of $44.38 and are up about 190% year to date; the six-month performance is 57%. With a market capitalization of roughly $2.03 billion, an InvestingPro analysis classifies the stock as overvalued, and analysts do not expect profitability this year. Several firms initiated or confirmed positive ratings and price targets (including William Blair $79.03, Leerink $52.00, Citizens $80.00, Truist $56.00, Stifel $56.00); phase-2 results for RAP-219 in bipolar mania are expected in Q4 2026. » Altro su de.investing.com
Rapport Therapeutics reaches all-time high at $44.28

Shares of Rapport Therapeutics rose to a record high of $44.28, giving a gain of about 177.11% over the past year. Market capitalization is roughly $2 billion, while earnings per share for the last twelve months are -$2.56. Analyst ratings vary: William Blair (outperform, fair value $79.03), Leerink (outperform, $52), Truist (buy, target $56), Stifel (buy, $56) and Citizens (market outperform, $80). InvestingPro classifies the stock as overvalued; quarterly results are expected in nine days. » Altro su de.investing.com
Rapport Therapeutics hits record high at $42.36

Shares of Rapport Therapeutics climbed to a record high of $42.36, reflecting a 266.84% increase over the past year and a market capitalization of about $1.93 billion. InvestingPro currently rates the stock as overvalued and does not expect profitability this year. The company moved forward the expected release of Phase‑2 results for RAP‑219 in bipolar mania to Q4 2026, raised recruitment targets and adjusted the statistical analysis plan. Several analysts reaffirmed or raised their ratings (including Stifel, Truist, Raymond James, Leerink, Citizens) and set price targets between $44 and $80. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Rapport Therapeutics ha registrato ricavi pari a 0,00€ e un utile netto di −49,61 Mio€

(EUR)	giu 2026	YoY
Ricavi	0,00	-
Utile lordo	0,00	-
Utile netto	−49,61 Mio	118,72%
EBITDA	−49,22 Mio	98,39%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+2,10 Mrd€
Numero di azioni	47,83 Mio
Massimo/minimo a 52 settimane	+44,11€ - +12,11€
Dividendi	No
Beta	0,97
Rapporto P/E	−16,83
Rapporto PEG	+0,78
Rapporto P/B	+5,74
Rapporto P/S	+122,37

Profilo aziendale

Rapport Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entdeckung und Entwicklung von bahnbrechenden niedermolekularen Medikamenten für Patienten mit Erkrankungen des zentralen Nervensystems (ZNS) konzentriert. Sein führender Produktkandidat ist das rezeptorassoziierte Protein (RAP)-219, ein kleines Molekül, das TARPy8-haltige AMPARs mit picomolarer Affinität hemmen soll, um fokale Epilepsie und andere ZNS-Erkrankungen zu behandeln, darunter periphere neuropathische Schmerzen und bipolare Störungen. Das Unternehmen entwickelt außerdem RAP-199, ein zielgerichtetes TARPy8-Molekül mit differenzierten chemischen und pharmakokinetischen Eigenschaften, sowie Programme für nikotinische Acetylcholinrezeptoren (nAChR), wie a6 nAChR zur Behandlung chronischer Schmerzen und a9a10 nAChR zur Behandlung von Hörstörungen. Das Unternehmen war früher als Precision Neuroscience NewCo, Inc. bekannt und änderte im Oktober 2022 seinen Namen in Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. wurde im Jahr 2022 gegründet und hat seinen Sitz in Boston, Massachusetts.